Trial Profile
Randomized phase II study comparing Gemcitabine versus TS-1 for advanced bile duct cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2019
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 08 Apr 2019 Status changed from recruiting to discontinued.
- 26 Jun 2012 Planned end date changed from 1 Jul 2013 to 1 Jan 2014 as reported by University Hospital Medical Information Network - Japan.
- 26 Jun 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.